Photo by nci from unsplash
2016;30(2):268-273. 5. Lamba J, Chauhan L, Shin M, et al. CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531… Click to show full abstract
2016;30(2):268-273. 5. Lamba J, Chauhan L, Shin M, et al. CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial. Blood. 2017;130(suppl 1): 3826. 6. Stanchina M, Pastore A, Devlin S, Famulare C, Stein E, Taylor J. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. J Hematol Oncol. 2019;12(1):85. 7. Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumabozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6): 1620-1627.
Journal Title: American Journal of Hematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!